Group 1 - The fifth China Shouxiangu Lingzhi Culture Festival was held in Hangzhou, showcasing the vibrant development of the Lingzhi industry through cultural markets, opening ceremonies, and Song Dynasty-themed banquets [1][3] - The festival creatively integrated traditional Chinese medicine culture with modern interactive experiences, allowing participants to appreciate the rich heritage of Lingzhi culture [3][5] - A highlight of the event was the Lingzhi Songyun Siya, featuring trendy products like Lingzhi coffee and various traditional entertainment projects, attracting many influencers [5] Group 2 - The "Songyun Elegant Banquet" included artistic performances that illustrated the legendary status of Lingzhi in traditional culture, emphasizing the cross-disciplinary appeal of "ancient recipes in modern cuisine" [5][7] - A panel discussion featured cross-industry guests discussing the modern relevance and influence of Lingzhi culture, highlighting its adaptability in contemporary life [7][9] - The festival launched the "Lingzhi Category Health Consumption White Paper," outlining standardized paths for the Lingzhi industry and proposing three major trends: technological advancement, youth engagement, and internationalization [9] Group 3 - The event focused on industry upgrades, with multiple organizations initiating the "Action Declaration for High-Quality Development of the Lingzhi Industry," emphasizing five key actions: technological innovation, quality supervision, industry-academia-research collaboration, market channel expansion, and cultural promotion [9] - A high-level academic exchange discussed the application prospects of wall-free Lingzhi spore powder in modern medicine, indicating a deep integration of traditional and modern medical practices [9] - The publication of "Shouxiangu Chronicles" documented the transformation of a century-old Chinese brand and the global journey of the Lingzhi industry [9]

公司代码：603896 公司简称：寿仙谷 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 Zhejiang Shouxiangu Pharmaceutical Co., Ltd. （浙江省武义县壶山街道商城路 10 号） 2024 年年度股东大会会议资料 二〇二五年五月十三日 浙江寿仙谷医药股份有限公司 2023 年年度股东大会会议资料 目 录 | 浙江寿仙谷医药股份有限公司 2024 年年度股东大会会议议程 1 | | --- | | 浙江寿仙谷医药股份有限公司 2024 年年度股东大会会议须知 3 | | 议案一：浙江寿仙谷医药股份有限公司董事会 2024 年度工作报告 5 | | 议案二：浙江寿仙谷医药股份有限公司监事会 年度工作报告 18 2024 | | 议案三：浙江寿仙谷医药股份有限公司 2024 年度财务决算报告 22 | | 议案四：浙江寿仙谷医药股份有限公司 2024 年度利润分配预案 28 | | 议案五：浙江寿仙谷医药股份有限公司 年年度报告（全文及摘要） 29 2024 | | 议案六：浙江寿仙谷医药股份有限公司 2025 年度日常关联交易预案 30 | ...

Core Viewpoint - The company experienced a significant decline in revenue and net profit in 2024, attributed to weak consumer demand, particularly affecting high-end products [1][2]. Financial Performance - In 2024, the company achieved revenue of 692 million yuan, a decrease of 11.81% year-on-year, and a net profit of 175 million yuan, down 31.34% from the previous year [1]. - For Q1 2025, revenue was 171 million yuan, a decline of 22.68% year-on-year, with a net profit of 58.37 million yuan, down 24.32% [1]. Product Category Analysis - High-end product sales, particularly Lingzhi spore powder, saw a more significant decline compared to mid- to low-end products. Lingzhi spore powder sales dropped by 16.46% to 446 million yuan in 2024 [2]. - Specific sales figures for Lingzhi spore powder products include: - Broken wall Lingzhi spore powder: 102 million yuan, down 20.23% - Broken wall Lingzhi spore powder: 221 million yuan, down 9.46% - Broken wall Lingzhi spore powder granules: 104 million yuan, down 24.46% - Broken wall Lingzhi spore powder slices: 18.63 million yuan, down 21.53% [2]. - Iron-clad Dendrobium products generated 113 million yuan in sales, a decrease of 11%, with specific declines in sales of Iron-clad Dendrobium granules and extracts [2]. Sales Volume and Pricing - The sales volume of Lingzhi spore powder products in 2024 was 25.72 tons, down 13.84%, with an average price of 17.33 yuan per gram, down 3.04% [3]. - Iron-clad Dendrobium products had a sales volume of 13.91 tons, up 7.33%, but the average price fell to 8.11 yuan per gram, down 17.08% [3]. Market Expansion and Strategy - The company reported that 65.23% of its revenue came from Zhejiang province, with only 9.61% from outside the province and 25.16% from online sales [3]. - Revenue growth rates for different regions showed declines: Zhejiang province down 7.52%, outside Zhejiang down 18.81%, and online sales down 19.51% [4]. - The company is restructuring its distributors and plans to enhance its presence in the provincial market through traditional and flagship store channels [4]. Competitive Advantage - The company has established a comprehensive supply chain model and developed proprietary technologies for its products, ensuring safety and efficacy [5]. - The company has cultivated 10 superior varieties of medicinal materials, including three types of Lingzhi and three types of Iron-clad Dendrobium [5]. - The unique low-temperature supersonic airflow breaking technology significantly enhances the absorption rates of active ingredients in its products compared to traditional methods [5]. Future Projections - Revenue projections for 2025-2027 are 732 million yuan, 815 million yuan, and 899 million yuan, representing year-on-year growth rates of 5.9%, 11.4%, and 10.2% respectively [6]. - Net profit forecasts for the same period are 191 million yuan, 219 million yuan, and 244 million yuan, with corresponding growth rates of 9.3%, 14.8%, and 11.4% [6].

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 1） 公司发布2024年报，营业收入6.92亿元，同比-11.81%；归母净利润1.75亿元，同比-31.34%；扣非归母净 利润1.43亿元，同比-36.96%；经营性净现金流2.13亿元，同比-32.25%；EPS（基本）0.88元。业绩符合市场预 期。 2） 公司发布2025年一季报，营业收入1.71亿元，同比-22.68%；归母净利润0.58亿元，同比-24.32%；扣非归 母净利润0.39亿元，同比-42.91%。业绩符合市场预期。 点评： 业绩短期承压，核心产品稳健支撑 2024Q1~2025Q1，公司单季度营业收入分别为2.21/1.32/1.19/2.20/1.71亿元，同比 +7.15%/-20.35 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's short-term performance is under pressure, but core products provide stable support. For the period from Q1 2024 to Q1 2025, the company's quarterly revenue figures are 221 million, 132 million, 119 million, 220 million, and 171 million yuan, showing a year-on-year change of +7.15%, -20.35%, -30.20%, -9.13%, and -22.68% respectively. The net profit attributable to the parent company for the same period is 77 million, 24 million, 18 million, 56 million, and 58 million yuan, with year-on-year changes of +23.19%, -14.05%, -63.77%, -51.32%, and -24.32% respectively. The poor performance is mainly attributed to changes in the macroeconomic environment and weak consumer demand [2][3] Summary by Relevant Sections Financial Performance - In 2024, the revenue from the company's core product categories shows a decline, with revenue from Ganoderma lucidum spore powder at 445 million yuan (65.75% of total revenue) down by 16.53% year-on-year, and revenue from Dendrobium candidum at 113 million yuan (16.63% of total revenue) down by 11.00% year-on-year. The sales model shows that the distribution model accounts for 58.57% (up 2.25 percentage points year-on-year), while direct sales (including online) account for 41.43%, with online sales at 171 million yuan (25.16% of total revenue) maintaining a stable layout [2] Marketing and International Expansion - The company is actively promoting marketing reforms and expanding its international presence. It continues to deepen the "famous doctors, famous medicines, famous stores" model, promoting the direct sales experience from Zhejiang to Shanghai and Jiangsu, and establishing a business pattern centered on Zhejiang with Shanghai and Jiangsu as wings. The company plans to add 10 specialty stores and strengthen cooperation with live streaming channels like Douyin and Li Jiaqi. In terms of internationalization, significant progress has been made in collaboration with the Mayo Clinic for research, advancing the commercialization of Ganoderma products in the U.S. and registering products in the EU [3] Profit Forecast and Valuation - The short-term recovery of consumer demand may impact the company's earnings elasticity. The net profit forecasts for 2025 and 2026 have been revised down to 192 million and 224 million yuan (originally forecasted at 355 million and 417 million yuan, both down by 46%). The newly added forecast for 2027 is a net profit of 251 million yuan, with year-on-year growth rates of 9.88%, 16.44%, and 12.23%. The current price corresponds to P/E ratios of 20, 17, and 15 times for 2025, 2026, and 2027 respectively. Given the company's product scarcity, technical standards barriers, and advantages in the entire industry chain, it has the ability to withstand cycles, and with policy support for traditional Chinese medicine, long-term growth is expected [3][4]

Investment Rating - The report maintains a rating of "Accumulate" for the company [5] Core Views - The company's short-term performance is under pressure, but core products provide stable support. The quarterly revenue from Q1 2024 to Q1 2025 shows fluctuations, with a peak of 2.21 billion yuan and a low of 1.19 billion yuan, reflecting a year-on-year change of +7.15% to -30.20%. The net profit also shows a decline, with a peak of 0.77 billion yuan and a low of 0.18 billion yuan, indicating a significant drop in profitability due to macroeconomic changes and weak consumer demand [2][3] - The company is advancing marketing reforms and expanding its international presence. It is implementing a "famous doctor, famous medicine, famous store" model and plans to enhance its presence in the Yangtze River Delta region. The internationalization efforts include collaboration with the Mayo Clinic and registration of products in the EU, which opens up overseas market opportunities [3][4] Financial Performance Summary - The company's revenue for 2024 is projected at 6.92 billion yuan, a decrease of 11.81% year-on-year, with a net profit of 1.75 billion yuan, down 31.34% [9] - The revenue for 2025 is estimated at 7.34 billion yuan, with a net profit of 1.92 billion yuan, reflecting a recovery trend with a growth rate of 9.88% in 2027 [4][10] - The earnings per share (EPS) for 2024 is expected to be 0.88 yuan, with a gradual increase to 1.27 yuan by 2027 [10][12] Profitability and Valuation Metrics - The company's gross margin is projected to be 80.7% in 2024, with a slight decline to 80.6% by 2027. The return on equity (ROE) is expected to improve from 7.6% in 2024 to 9.0% in 2027 [12][13] - The price-to-earnings (P/E) ratio is forecasted to be 22 in 2024, decreasing to 15 by 2027, indicating a more attractive valuation over time [12][13] Market Position and Strategy - The company is focusing on enhancing its sales channels, with a significant portion of revenue coming from e-commerce, which accounted for 25.16% of total sales in the latest quarter. The company plans to open 10 new specialty stores and strengthen partnerships with online influencers [2][3] - The geographical revenue distribution shows that 65.23% of income comes from Zhejiang province, with ongoing efforts to reform distributors in other provinces like Guangdong and Anhui [2][3]

Group 1 - Shenjian Co., Ltd. reported a net profit of 33.65 million yuan for 2024, a year-on-year increase of 32.29%, with a proposed cash dividend of 0.5 yuan per 10 shares [1] - Jingce Electronics experienced a net loss of 97.60 million yuan in 2024, transitioning from profit to loss, despite a revenue increase of 5.59% to 2.565 billion yuan [1] - Jingwei Co., Ltd. reported a net profit of 35.54 million yuan for 2024, a decrease of 36.76%, with a proposed cash dividend of 1.00 yuan per 10 shares [1][2] Group 2 - Minsheng Health achieved a net profit of 91.83 million yuan in 2024, a year-on-year increase of 7.24%, with a proposed cash dividend of 1.00 yuan per 10 shares [2] - Zhongshe Co., Ltd. reported a net profit of 10.16 million yuan for 2024, a decline of 76.24%, with a proposed cash dividend of 0.2 yuan per 10 shares [3] - Keyuan Smart reported a net profit of 252 million yuan for 2024, a year-on-year increase of 56.64%, with a proposed cash dividend of 0.4 yuan per 10 shares [4] Group 3 - Beilu Pharmaceutical reported a net profit of 14.54 million yuan for Q1 2025, a year-on-year increase of 26.13%, with revenue of 283 million yuan [5] - Wangsu Technology achieved a net profit of 192 million yuan for Q1 2025, a year-on-year increase of 38.54%, with revenue of 1.235 billion yuan [6] - Keyuan Pharmaceutical reported a net profit of 23.08 million yuan for Q1 2025, a year-on-year increase of 7.25%, despite a revenue decline of 23.98% [7] Group 4 - Guangting Information reported a net profit of 24.03 million yuan for Q1 2025, turning from loss to profit, with revenue of 134 million yuan [9] - Zhaori Technology reported a net loss of 1.23 million yuan for Q1 2025, with revenue of 35.23 million yuan [11] - Huakai Yibai reported a net loss of 15.09 million yuan for Q1 2025, despite revenue growth of 35.08% to 2.292 billion yuan [13] Group 5 - Xinhongye reported a net profit of 34.43 million yuan for Q1 2025, a year-on-year increase of 20.43%, with revenue of 755 million yuan [15] - Huning Co., Ltd. reported a net profit of 3.61 million yuan for Q1 2025, a year-on-year decrease of 45.68%, with revenue of 64.51 million yuan [16] - Camel Co., Ltd. reported a net profit of 237 million yuan for Q1 2025, a year-on-year increase of 51.89%, with revenue of 4.136 billion yuan [17] Group 6 - Hengtong Co., Ltd. reported a net profit of 42.55 million yuan for Q1 2025, a year-on-year increase of 51.62%, with revenue of 313 million yuan [19] - Changqing Technology reported a net profit of 35.38 million yuan for Q1 2025, a year-on-year decrease of 23.80%, with revenue of 246 million yuan [21] - Libaba Co., Ltd. reported a net profit of 34.72 million yuan for Q1 2025, a year-on-year increase of 9.91%, with revenue of 419 million yuan [22] Group 7 - Shouxiangu reported a net profit of 58.37 million yuan for Q1 2025, a year-on-year decrease of 24.32%, with revenue of 171 million yuan [24] - Bojun Technology announced a stock issuance application accepted by the Shenzhen Stock Exchange [24] - Dayou Energy announced the full resumption of production at its Gengcun coal mine, with an annual production capacity of 3.6 million tons [25] Group 8 - Deyang Co., Ltd. successfully acquired land use rights for industrial land in Ningbo for 45.80 million yuan [27] - Tianyu Pharmaceutical's subsidiary received a drug registration certificate for an injectable product [29] - Xingwang Yuda signed a strategic cooperation agreement with the Jilin Province Bionic Robot Innovation Center [30] Group 9 - Lifang Pharmaceutical received approval for clinical trials of a new drug [32] - Zai Sheng Technology reported a net profit of 33.56 million yuan for Q1 2025, a year-on-year increase of 3.69%, with revenue of 324 million yuan [34] - Jinxin Technology reported a net profit of 319,920 yuan for Q1 2025, turning from loss to profit, with revenue of 563 million yuan [36] Group 10 - Huayin Electric reported a net profit of 75.67 million yuan for Q1 2025, a year-on-year increase of 894.61%, with revenue of 2.307 billion yuan [37] - Xinghua Co., Ltd. reported a net loss of 95.51 million yuan for Q1 2025, with revenue of 840 million yuan [38] - Heren Technology reported a net loss of 384,410 yuan for Q1 2025, with revenue of 78.40 million yuan [40] Group 11 - Fenda Technology reported a net profit of 40.45 million yuan for Q1 2025, a year-on-year increase of 84.07%, with revenue of 760 million yuan [41] - Tongda Co., Ltd. reported a net profit of 25.49 million yuan for 2024, a year-on-year decrease of 69.15%, with revenue of 6.201 billion yuan [43] - Zhonghe Holdings reported a net profit of 283 million yuan for 2024, a year-on-year decrease of 54.69%, with a proposed cash dividend of 0.3 yuan per 10 shares [44] Group 12 - Jiantou Energy reported a net profit of 531 million yuan for 2024, a year-on-year increase of 181.59%, with a proposed cash dividend of 1.3 yuan per 10 shares [44] - Guanghua Technology reported a net loss of 205 million yuan for 2024, with revenue of 2.589 billion yuan [45] - Huajin Technology reported a net profit of 29.26 billion yuan for 2024, a year-on-year increase of 8.1%, with a proposed cash dividend of 9 yuan per 10 shares [46] Group 13 - Yingke Medical reported a net profit of 1.465 billion yuan for 2024, a year-on-year increase of 282.63%, with a proposed cash dividend of 1.00 yuan per 10 shares [46] - Solar Energy reported a net profit of 1.225 billion yuan for 2024, a year-on-year decrease of 22.38%, with a proposed cash dividend of 0.56 yuan per 10 shares [46] - Dongfang Electric reported a net profit of 318 million yuan for 2024, a year-on-year decrease of 50.62%, with a proposed cash dividend of 0.32 yuan per 10 shares [47] Group 14 - Tianneng Heavy Industry reported a net loss of 262 million yuan for 2024, with revenue of 3.273 billion yuan [48] - Gangyan High-tech reported a net profit of 249 million yuan for 2024, a year-on-year decrease of 22.08%, with a proposed cash dividend of 1.00 yuan per 10 shares [48] - Shihua Machinery reported a net profit of 96.88 million yuan for 2024, a year-on-year increase of 5.35%, with revenue of 8.037 billion yuan [49] Group 15 - Gongtong Pharmaceutical reported a net loss of 27.59 million yuan for 2024, with revenue of 537 million yuan [51] - Zhongjing Electronics reported a net loss of 87.43 million yuan for 2024, with revenue of 2.932 billion yuan [53] - Yudai Development reported a net loss of 114 million yuan for 2024, with revenue of 388 million yuan [55] Group 16 - Zhenhua Technology reported a net profit of 970 million yuan for 2024, a year-on-year decrease of 63.83%, with a proposed cash dividend of 1.8 yuan per 10 shares [56] - Jierong Technology reported a net loss of 298 million yuan for 2024, with revenue of 1.357 billion yuan [58] - Changgao Electric New reported a net profit of 252 million yuan for 2024, a year-on-year increase of 45.66%, with a proposed cash dividend of 0.8 yuan per 10 shares [60] Group 17 - Shibao Detection announced a plan to acquire 81% of Zhonghuan Lianshu for 52.65 million yuan [61] - Jiangsu Boyun announced a plan to reduce its shareholding by up to 3% [62] - Jingfeng Mingyuan announced a plan to acquire 100% of Yichong Technology for 3.283 billion yuan [63]

Revenue and Profit - Revenue for Q1 2025 was CNY 170,805,352, a decrease of 22.68% compared to CNY 220,901,649 in the same period last year[4] - Net profit attributable to shareholders was CNY 58,373,966, down 24.32% from CNY 77,130,242 year-on-year[4] - Basic earnings per share decreased by 25.64% to CNY 0.29 from CNY 0.39 in the previous year[6] - Total operating revenue for Q1 2025 was ¥170,805,352, a decrease of 22.7% compared to ¥220,901,649 in Q1 2024[18] - Net profit for Q1 2025 was ¥58,373,966, down 24.2% from ¥77,130,242 in Q1 2024[19] - Operating profit for Q1 2025 was ¥58,308,200, compared to ¥76,696,519 in Q1 2024, reflecting a decline of 24.0%[18] - Basic and diluted earnings per share for Q1 2025 were both ¥0.29, down from ¥0.39 in Q1 2024[19] - Other comprehensive income after tax for Q1 2025 was ¥843,980, significantly lower than ¥10,703,351 in Q1 2024[19] Cash Flow - Operating cash flow increased by 42.52% to CNY 70,177,811 from CNY 49,240,931 in the same period last year[4] - Cash flow from operating activities increased to ¥70,177,811 in Q1 2025, up 42.5% from ¥49,240,931 in Q1 2024[22] - Cash flow from investing activities showed a net outflow of ¥97,041,004 in Q1 2025, compared to a net inflow of ¥132,590,452 in Q1 2024[23] - Cash flow from financing activities resulted in a net outflow of ¥97,463,057 in Q1 2025, compared to a smaller outflow of ¥7,819,456 in Q1 2024[23] - The ending cash and cash equivalents balance for Q1 2025 was ¥181,964,934, down from ¥750,080,016 at the end of Q1 2024[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,115,726,946, a slight decrease of 0.49% from CNY 3,131,185,579 at the end of the previous year[6] - The company's current assets totaled CNY 1,445,028,686.42, down from CNY 1,522,348,721.66 at the end of 2024, indicating a decrease of approximately 5.08%[13][15] - Cash and cash equivalents decreased to CNY 731,501,989.37 from CNY 853,642,354.80, representing a decline of about 14.3%[13][15] - The company's total liabilities decreased to CNY 762,488,777.80 from CNY 837,166,235.48, reflecting a reduction of approximately 8.9%[15] - The company's inventory rose to CNY 197,370,499.01 from CNY 179,550,878.25, indicating an increase of approximately 9.9%[13][15] - The accounts receivable decreased to CNY 79,297,754.72 from CNY 86,360,292.67, a decline of about 8.3%[13][15] - The company reported a significant reduction in short-term borrowings, which fell to CNY 94,794,120.21 from CNY 187,400,276.58, a decrease of approximately 49.5%[15] - The company's long-term investments slightly decreased to CNY 4,978,640.07 from CNY 5,003,440.74, a decline of about 0.5%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,469[10] - Shareholders' equity attributable to shareholders increased by 2.58% to CNY 2,353,238,168 from CNY 2,294,019,344 at the end of the previous year[6] - The equity attributable to shareholders increased to CNY 2,353,238,168.26 from CNY 2,294,019,344.33, marking an increase of about 2.57%[15] - The company has not reported any significant changes in shareholder relationships or participation in financing activities during the reporting period[11][12] Accounts Receivable and Borrowings - Accounts receivable increased by 33.75%, mainly due to an increase in outstanding receivables at the end of the reporting period[8] - Short-term borrowings decreased by 49.42%, attributed to a reduction in pledged bank acceptance bills[8]

寿仙谷（603896）公告，2025年第一季度营收为1.71亿元，同比下降22.68%；净利润为5837.4万元，同 比下降24.32%。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][15] Core Views - The company achieved a revenue of 692 million yuan in 2024, a year-on-year decrease of 11.81%, with a net profit attributable to shareholders of 175 million yuan, down 31.34% [7] - The gross margin for 2024 was 80.72%, a decrease of 2.00 percentage points, while the net margin was 25.26%, down 7.19 percentage points [7] - The company is expected to see growth driven by marketing reforms in provinces outside of Zhejiang, despite short-term sales pressure [7] Financial Performance Summary - Revenue for 2024 was 692 million yuan, with a year-on-year decline of 11.81% [11] - Net profit attributable to shareholders for 2024 was 175 million yuan, down 31.34% [11] - The company forecasts net profits of 208 million yuan, 240 million yuan, and 274 million yuan for 2025, 2026, and 2027 respectively [7][11] - The earnings per share (EPS) are projected to be 1.05 yuan, 1.21 yuan, and 1.38 yuan for 2025, 2026, and 2027 respectively [7][11] Product and Market Analysis - Revenue from Ganoderma lucidum spore powder products decreased by 16.53% to 445 million yuan in 2024 [8] - Revenue from Dendrobium candidum products fell by 11.00% to 113 million yuan [8] - The company plans to enhance its sales model and marketing strategies to expand its market presence outside of Zhejiang [8] Clinical Research and Internationalization - Clinical research on the anti-tumor effects of Ganoderma lucidum spore powder is progressing well, involving 17 top-tier hospitals [9] - The company is collaborating with the Mayo Clinic on research related to cardiovascular disease treatment using its products [9]